Recombinant tissue plasminogen activator in the treatment of pleural infections in adults - 08/08/11
, George Kouliatsis a, Paschalis Steiropoulos a, Stavros Anevlavis a, Athanasia Pataka a, Maria Popidou a, Demitrios Mikroulis b, Ioannis Pneumatikos c, Demosthenes Bouros a
Corresponding author. Department of Pneumonology, University Hospital of Alexandroupolis, 68100 Alexandroupolis, Greece. Tel./fax: +30 2551075096.Summary |
Background |
Intrapleural recombinant tissue plasminogen activator (r-TPA) has been successfully evaluated in pediatric patients with complicated parapneumonic pleural effusion (CPE) and pleural empyema (PE). Yet, there is no data concerning r-TPA in adults with CPE/PE. The aim of our study was to investigate the efficacy and complications of r-TPA in adult patients with CPE/PE.
Methods |
Twenty consecutive patients (mean age 50±18.9 years) with pleural infection (14 CPE and 6 PE) were included. Chest tube was inserted under guidance of chest ultrasound and/or computed tomography. After failure of pleural fluid drainage, 25mg of r-TPA was administered intrapleurally in a single daily dose. The evaluation was made according to imaging and clinical status.
Results |
The mean volume of fluid increased significantly after r-TPA administration (p<0.0001). White blood cells count (WBC) and C-reactive protein (CRP) were significantly improved after r-TPA instillations (both p<0.0001). Significant clinical and imaging improvement was noted in all but one patient after r-TPA administration (overall p<0.0001). Complications observed were mild: pain in 4 (25%) and local bleeding in 3 (15%) patients. The median number of r-TPA instillations was 3 (range 2–5).
Conclusion |
Intrapleural instillation of r-TPA at a dose of 25mg is a well-tolerated and effective treatment in 95% of our adult patients with CPE/PE.
Le texte complet de cet article est disponible en PDF.Keywords : r-TPA, Empyema, Fibrinolytics, Pleural infection, Parapneumonic effusion, Actilyse
Plan
Vol 102 - N° 12
P. 1694-1700 - décembre 2008 Retour au numéro
Article précédent
- Achieving asthma control in practice: Understanding the reasons for poor control
- John Haughney, David Price, Alan Kaplan, Henry Chrystyn, Rob Horne, Nick May, Mandy Moffat, Jennifer Versnel, Eamonn R. Shanahan, Elizabeth V. Hillyer, Alf Tunsäter, Leif Bjermer
- Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD
- Claudio Terzano, Angelo Petroianni, Vittoria Conti, Daniela Ceccarelli, Elda Graziani, Alessandro Sanduzzi, Serena D'Avelli
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?